Home Alzheimer’s Disease Larotrectinib Demonstrates Limited Benefit in Patients with NTRK Alterations

Larotrectinib Demonstrates Limited Benefit in Patients with NTRK Alterations

In a data analysis presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting, held from April 27-28, 2020, researchers suggested that larotrectinib (Vitrakvi) is highly effective in patients with NTRK gene fusions and has demonstrated durable responses.1

However, in patients with other non-fusion NTRK alterations, including point mutations and amplifications, larotrectinib offered only limited benefit.

NTRK gene fusions are found at high frequencies at 90% or more in rare tumor types such as secretory breast carcinoma and infantile fibrous sarcoma, and at lower frequencies, generally less than 1%, in a range of other common tumor types, including lung and colorectal cancers,” David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, said in a poster presentation of the data at AACR.2

Data for the trial were pooled from 3 clinical…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments